Ubrigene Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 300

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $27.5M

  • Investors
  • 23

Ubrigene General Information

Description

Provider of gene and cell therapy contract research intended to assist drug development companies. The company's platform utilizes GMP-compliant facilities and proprietary viral vector technologies to support plasmid production, cell therapy development and mRNA manufacturing, thereby enabling pharmaceutical enterprises to outsource research and improve drug discovery efficiency.

Contact Information

Website
www.ubrigene.cn
Formerly Known As
Yiming (Beijing) Cell Biotechnology, Yiming Cell Biotechnology, Jiangsu Yiming Biotechnology, Beijing Yiming Cell Biotechnology, Yiming (Beijing) Biomedical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 3, Area A, Phase III of the Biomedical Industrial Park
  • Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu
  • China
+86 400
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Building 3, Area A, Phase III of the Biomedical Industrial Park
  • Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, Jiangsu
  • China
+86 400

Ubrigene Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ubrigene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 24-Dec-2024 $27.5M Completed Generating Revenue
8. Later Stage VC (Series C1) 18-Apr-2023 Completed Generating Revenue
7. Later Stage VC (Series C) 27-Sep-2022 Completed Generating Revenue
6. Later Stage VC (Series B) 17-Mar-2021 Completed Generating Revenue
5. Later Stage VC (Series A) 04-Nov-2020 Completed Generating Revenue
4. Secondary Transaction - Private 12-Oct-2020 Completed Generating Revenue
3. Early Stage VC 18-Oct-2019 Completed Generating Revenue
2. Early Stage VC 05-Dec-2018 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Ubrigene’s complete valuation and funding history, request access »

Ubrigene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of gene and cell therapy contract research intended to assist drug development companies. The company's platfor
Other Pharmaceuticals and Biotechnology
Suzhou, China
300 As of 2024

Shanghai, China
 

Nanjing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ubrigene Competitors (2)

One of Ubrigene’s 2 competitors is OBiO Technology, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OBiO Technology Formerly VC-backed Shanghai, China
GenScript Formerly VC-backed Nanjing, China
You’re viewing 2 of 2 competitors. Get the full list »

Ubrigene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ubrigene Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Romulus Venture Partners Growth/Expansion
Anhui Jiaokong Jinshi Private Equity Fund Management PE/Buyout Minority
China Industrial Asset Management Asset Manager Minority
Ciit Asset Management Asset Manager Minority
Guotai Junan Innovation Investment Growth/Expansion Minority
You’re viewing 5 of 23 investors. Get the full list »

Ubrigene Investments (1)

Ubrigene’s most recent deal was a Corporate Asset Purchase with Mustang Bio (Manufacturing Facility in Worcester) for . The deal was made on 28-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mustang Bio (Manufacturing Facility in Worcester) 28-Jul-2023 Corporate Asset Purchase Buildings and Property
To view Ubrigene’s complete investments history, request access »

Ready to get started?

Request a free trial

Ubrigene FAQs

  • When was Ubrigene founded?

    Ubrigene was founded in 2015.

  • Where is Ubrigene headquartered?

    Ubrigene is headquartered in Suzhou, China.

  • What is the size of Ubrigene?

    Ubrigene has 300 total employees.

  • What industry is Ubrigene in?

    Ubrigene’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Ubrigene a private or public company?

    Ubrigene is a Private company.

  • What is Ubrigene’s current revenue?

    The current revenue for Ubrigene is .

  • How much funding has Ubrigene raised over time?

    Ubrigene has raised $142M.

  • Who are Ubrigene’s investors?

    Romulus Venture Partners, Anhui Jiaokong Jinshi Private Equity Fund Management, China Industrial Asset Management, Ciit Asset Management, and Guotai Junan Innovation Investment are 5 of 23 investors who have invested in Ubrigene.

  • Who are Ubrigene’s competitors?

    OBiO Technology and GenScript are competitors of Ubrigene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process